Cumulative updating of approved biopharmaceuticals
Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by recombinant technologies.Other 1300 recombinant pharmaceuticals are under development, with a clear tendency towards engineered versions with improved performance and new functionalities regarding the conventional, plain protein species.In humans, such diseases can be treated by the clinical administration of the missing protein from external sources, to reach ordinary concentrations at systemic or tissular levels .Therefore, many human proteins have an important pharmaceutical value but they are difficult to obtain from their natural sources.Course Information: Satisfactory/Unstatisfatory grading only. Prerequisite(s): Consent of the instructor supervising the research experience. Course Information: Credit is not given for BPS 382 if the student has credit for PSOP 382 or PMMP 382. Discusses relevant educational and professional issues. Course Information: Credit is not given for BPS 383 if the student has credit for PSOP 383 or PMMP 383. Discusses with advisees relevant educational and professional issues. Explore pharmacy career opportunities with invited guests. Overview of drug development process from target identification and screening through clinical trials and FDA evaluation. Emphasis will be placed on the regulatory aspects of drug development including clinical trials, FDA approval and post marketing surveillance. Evaluates social policies and regulatory issues surrounding drug abuse. Prerequisite(s): Minimum cumulative grade point average of 2.50 and consent of the instructor, department head, and Associate Dean for Student Affairs. Students create/update Curriculum Vitae; explore various pharmacy career opportunities. Weekly seminar series for second professional year pharmacy students. Thermodynamics, kinetics, colloid and surface chemistry in evaluation of pharmaceutical formulations.
This can be done in convenient microbial cells such as bacteria and yeasts, whose cultivation can be accomplished by relatively simple procedures and instrumentation.Most of the hosts used to produce the 151 recombinant pharmaceuticals so far approved for human use by the Food and Drug Administration (FDA) and/or by the European Medicines Agency (EMEA) are microbial cells, either bacteria or yeast.This fact indicates that despite the diverse bottlenecks and obstacles that microbial systems pose to the efficient production of functional mammalian proteins, namely lack or unconventional post-translational modifications, proteolytic instability, poor solubility and activation of cell stress responses, among others, they represent convenient and powerful tools for recombinant protein production. Designed to provide an introduction to the major classes of therapeutic agents. The major classes of receptors and their ligands (agonists and antagonists) that result in pharmacological effects and drug action. Investigation, under the direction of one or more faculty members, of a problem of limited scope. Students may register in more than one section per term. Theories and testing of the release of drug from solid dosage forms including the effect of dissolution rate on bioavailability. Prerequisite(s): Student must be listed as an advisee of the instructor. Prerequisite(s): Student must be listed as an advisee of the instructor. Course Information: Credit is not given for BPS 384 if the student has credit for PSOP 384 or PMMP 384. Recommended to graduate students with no industrial experience.